TABLE 1.
Characterization of A-I dHDL and A-I/A-II dHDL particles used in the study
| Particle | Particle diameter by PAGEa | Numer of apoA-I and apoA-II molecules per particleb |
Composition PC/A-I/A-IIc | |
|---|---|---|---|---|
| ApoA-I | ApoA-II | |||
| Å | ||||
| A-I dHDL | 101 ± 1 | 2 | 0 | 75/1 |
| A-I/A-II dHDL | 101 ± 2 | 2 | 1 | 147/2/1 |
a Particle diameters were calculated from native PAGE of particles with respect to a known set of high Mr standards (GE Healthcare, catalog number 17-0445-01). Three sets of independently generated particles, including the one shown on Fig. 1, were used.
b The number of apoA-I molecules in A-I dHDL were determined by particle cross-linking followed by MALDI-MS (Fig. 2A). The average molar ratio of apoA-I:apoA-II in A-I/A-II dHDL and the number of apolipoprotein molecules per A-I/A-II dHDL particle were determined as explained under “Experimental Procedures.”
c Particle compositions were calculated as described under “Experimental Procedures.” The composition of A-I dHDL was determined after the repurification process. The composition of A-I/A-II dHDL was determined after apoA-II incorporation into A-I dHDL without any further purification.